ArticleEuropean journal of nuclear medicine and molecular imaging2026
Clinical added value of LAFOV PET/CT in patients undergoing same-day [18 F]FDG SAFOV PET/CT scans: an initial experience report and explorative study.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From sensitivity gain to clinical decisions: total-body and long-axial-field-of-view PET/CT for diagnosis and image-based management in oncology and systemic disease.Annals of nuclear medicine · 2026Review
- Realization of long axial field-of-view PET technology in the clinic and research environment.The British journal of radiology · 2026Review
- Spatiotemporal voxel-wise concordance betweenEuropean journal of nuclear medicine and molecular imaging · 2026Article
- The Rise of Total-Body PET/CT: Advancing Molecular Imaging Toward Early Cancer Detection and Potential Future Application in Prevention Healthcare.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe uEXPLORER is the first total-body, long-axial field-of-view (LAFOV) PET/CT system available for diagnostic use. The present study aims to assess its clinical impact, with a particular focus on management changes resulting from its use in routine diagnostic workflows.
methodsFrom June to December 2024, consecutive patients undergoing [18 F]FDG PET/CT for both oncologic and non-oncologic indications were considered for paired acquisitions using short-axial field-of-view (SAFOV) and LAFOV (uEXPLORER) systems. Scans were independently reviewed by three nuclear medicine physicians. Per-patient and per-lesion analyses were performed. Subsequent clinical management decisions were evaluated to determine the impact of LAFOV imaging. Statistical analyses included kappa statistics, Wilcoxon Signed-Rank Test, and Spearman's correlation coefficient.
resultsA total of 124 patients (64% female; median age 65.5 years) were enrolled. Inter-reader agreement was substantial for SAFOV scans (Fleiss' k = 0.787) and almost perfect for LAFOV scans (Fleiss' k = 0.853). In per-patient analysis, the two scans were concordant in 85% of cases (Cohen's k = 0.73). Total lesions identified were 274 on SAFOV PET/CT and 323 on LAFOV PET/CT. Compared to SAFOV, LAFOV imaging detected 52 additional findings in 27 patients (p < 0.05). The per-lesion agreement was 76% (p < 0.05). Of the additional lesions identified by LAFOV PET/CT, 42% were confirmed as true positive. LAFOV findings led to changes in clinical management in 15% of patients, including major therapeutic changes in 68% of these cases.
conclusionLAFOV PET/CT significantly improved lesion detection and influenced clinical decision-making. Further prospective studies are required to validate these findings and fully assess LAFOV systems clinical utility.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.